Phaseline

Targets › FFAR4

FFAR4 (Free fatty acid receptor 4): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 4, 1 Phase 3; Psychiatry, Infectious disease; next expected readout Dec 2026.

[Isoform 2]: G protein-coupled receptor for long-chain fatty acids (LCFAs) with a major role in adipogenesis, energy metabolism and inflammation. Signals via G protein and beta-arrestin pathways. (UniProt, Q5NUL3)

Open in Phaseline: the race on FFAR4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Samuel FortinMonoglyceride Eicosapentaenoic acid (MAG-EPA)
Omega-3 fatty acid that activates free fatty acid receptors and reduces inflammation throu
FFAR1, FFAR4Phase 4Brain FogMay 2027
Ottawa Heart Institute Research CorporationIcosapent Ethyl (Vascepa)
Triglyceride-lowering agent; omega-3 fatty acid
FFAR1, FFAR4Phase 3InflammationDec 2026

Conditions

Brain Fog (1) Inflammation (1)

Modalities

small molecule (1)

Companies

Samuel Fortin (1) Ottawa Heart Institute Research Corporation (1)

Related targets

FFAR1 (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.